Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on May 29, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Three Class I directors elected through 2029: Mark McKenna, Cameron Turtle, and Laurie Stelzer.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Three Class I directors elected through 2029: Mark McKenna, Cameron Turtle, and Laurie Stelzer
- Executive compensation approved advisory basis, with 62,075,459 votes for
- KPMG LLP ratified as independent auditor for 2026, with 68,430,566 votes for
- AR ESPP approved overwhelmingly, with 66,885,864 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.